CADL

4.9703.12%
NL

Nicoletta Loggia

Independent Director

Dr. Nicoletta Loggia, PhD, RPh, is Chief Technical Officer of Orchard Therapeutics plc from September 09, 2021. Dr. Loggia has been Independent Director at Candel Therapeutics, Inc. since June 07, 2023. Dr. Loggia joined the Orchard Therapeutics plc in September 2021. She served as the Global Head of Cell And Gene Therapies at Novartis, where she held positions of increasing responsibility since 2004 and she led multidisciplinary international teams responsible for the end-to-end technical development, manufacturing and project management of several gene and cell therapies, including lentivirus, adeno-associated virus (AAV), stem and CAR-T cell processes, from concept to commercialization. She oversaw the integration of the CAR-T teams and AveXis’ AAV technical capabilities into Novartis’ technical research and development. She also oversaw the integration of the CAR-T teams and AveXis’ AAV technical capabilities into Novartis’ technical R&D. Previously, Dr. Loggia was global head of technical development novel biologic entities and cell and gene therapies where she was responsible for the early phase development of biologics and gene therapies. Her broad industry experience encompasses global leadership in the development and manufacturing of sterile drug products and devices and approvals of several commercial assets. Dr. Loggia began her career in the biopharmaceutical industry as a formulation scientist at Pfizer. She earned her Ph.D. in pharmaceutical technologies from the University of Pavia in Italy. She is a registered pharmacist and member of the UK Royal and Italian Pharmaceutical societies.

Positions